RxDoctor Payments Data

Carie Brown

Family · Kenansville, NCNPI 1750849758

Payments from drug & device makers

$5,590in general payments, 2019–2025

Across 372 payments — averaging $15.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$803
  • Pfizer$596
  • AbbVie$562
  • AstraZeneca$522
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$449
  • Astellas Pharma US Inc$331
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$5,590100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,590 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$53,159
Medicare patients
148
Services billed
739

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide117$144,349
MounjaroTirzepatide64$67,842
JardianceEmpagliflozin42$42,670
RybelsusSemaglutide19$29,736
FarxigaDapagliflozin Propanediol31$26,699
WegovySemaglutide18$23,909
NuedextaDextromethorphan Hbr/Quinidine13$23,537
XareltoRivaroxaban12$18,695
Breztri AerosphereBudesonide/Glycopyr/Formoterol25$17,994
EliquisApixaban28$17,756
LinzessLinaclotide17$16,952
Xigduo XrDapaglifloz Propaned/Metformin18$15,029
GraliseGabapentin11$13,269
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$10,401
GemtesaVibegron20$9,245

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Wegovy$803$197,993154 claims
Lilly USA, LLCMounjaro$110$67,84264 claims
Boehringer IngelheimJardiance, Glyxambi$61$48,99353 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$522$47,76469 claims
GSKTrelegy Ellipta, Breo Ellipta$152$19,18826 claims
AbbVieLinzess, Synthroid$562$18,40241 claims
PfizerEliquis$596$17,75628 claims
Almatica Pharma LLCGralise$14$13,26911 claims
Sumitomo Pharma America, Inc.Gemtesa$114$9,24520 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$12$1,480170 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.

Other family in Kenansville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →